%0 Journal Article
%T Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report
%A Steven R. Schuster
%A Barbara A. Pockaj
%A Mary R. Bothe
%A Paru S. David
%A Donald W. Northfelt
%J Journal of Personalized Medicine
%D 2012
%I MDPI AG
%R 10.3390/jpm2030071
%X Breast cancer is the most common malignancy among women in the United States with the second highest incidence of cancer-related death following lung cancer. The decision-making process regarding adjuvant therapy is a time intensive dialogue between the patient and her oncologist. There are multiple tools that help individualize the treatment options for a patient. Population-based analysis with Adjuvant! Online and genomic profiling with Oncotype DX are two commonly used tools in patients with early stage, node-negative breast cancer. This case report illustrates a situation in which the population-based prognostic and predictive information differed dramatically from that obtained from genomic profiling and affected the patient¡¯s decision. In light of this case, we discuss the benefits and limitations of these tools.
%K breast cancer
%K genomic profiling
%K medical decision-making
%K Oncotype DX
%K chemotherapy
%K personalized medicine
%U http://www.mdpi.com/2075-4426/2/3/71